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Pulmonary arterial hypertension (PAH) includes a series of
clinical conditions characterized by progressive increase of
pulmonary vascular resistance (PVR) leading to right heart
failure and premature death (1). In the past 15 years,
multiple randomized controlled studies (RCT) have been
performed in this ﬁeld resulting in the regulatory approval of
8 drugs of 3 pharmacological classes: endothelin receptor
antagonists, phosphodiesterase type-5 inhibitors, and pros-
tanoids (1). Meta-analyses of RCTs with approved drugs,
utilized either as monotherapy (2) or in combination (3),
have shown improvements in all-cause mortality or clinical
worsening, respectively. Despite these important progresses in
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medical therapy, many patients with PAH remain with
relevant symptoms and poor outcome. Interventional re-
sources such as lung transplantation are effective when
medical therapy fails, but the shortage of organ donors limits
the number of such procedures.
In this issue of the Journal, Chen et al. (4) present their
experience with pulmonary artery denervation (PADN) in
13 patients with idiopathic PAH. PADN is an interven-
tional procedure aimed to obliterate the nerve ﬁbers into the
vessel wall of the main pulmonary arteries by a dedicated
7.5-F multiple-function (temperature sensor and radio-
frequency ablation) catheter positioned through a peripheral
vein (patent application in progress). The authors apparently
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Actelion, Bayer, and GlaxoSmithKline.reduction of mean pulmonary arterial pressure (PAP), and
improvement of the 6-min walk distance and of the Tei
index in the 13 patients treated as compared with the 8 who
refused the procedure. These unexpectedly favorable results
need to be analyzed together with the relevant and multiple
limitations of the study.
Firstly, the biological plausibility of these effects is not
clear. In fact, in idiopathic PAH patients who are “nonre-
sponders” to the acute vasoreactivity test (such as those
enrolled in this study), the main mechanism for the increase
of the PAP and the PVR is related to the ﬁxed proliferative
and obstructive lesions of the distal pulmonary arteries and
not to functional and potentially reversible vasoconstriction
(1). In this setting, a hypothetical “pulmo-pulmonary baro-
receptor reﬂex” that originates in the large pulmonary
arteries has never been demonstrated. Theoretically, PADN
may abolish a functional vasoconstriction but may hardly
induce a reverse remodeling of the severe, ﬁxed obstructive
lesions in the distal pulmonary arteries.
The same authors have recently published a study on an
animal model (Mongolian dogs) in which they were able
to acutely induce an increase in PAP and PVR by occlu-
sion of the left pulmonary interlobar artery (5). After
PADN, the increase was no longer reproduced. However,
this acute model cannot be considered representative of
the chronic increase in PAP and PVR observed in idio-
pathic PAH patients that do not respond to the vaso-
reactivity test.
The characteristics of the patient population of the Chen
et al. study (4) are unusual for a group who carry the diagnosis
of idiopathic PAH. In fact, 13 of 21 patients (62%) were men
(men are not more than 30% to 35% of the population in
most idiopathic PAH series), all patients were on long-term
oxygen therapy (utilized by no more than 30% of patients in
most idiopathic PAH series), and the interval between initial
symptoms and PADN was on average about 6.8 years (long-
term survivors?) It is also highly unusual that a patient
population of idiopathic PAH deﬁned in the methods as
“not responding optimally to current medical therapy” have
normal right atrial pressures at rest. In addition, 5 of 8
patients (63%) who refused PADN (control group) were
hospitalized after 1 week of follow-up (see Table 4 of Chen
et al. [1]). All these discrepancies raise questions concerning
the correctness of the diagnosis of idiopathic PAH and the
nature of the control group.
As acknowledged by the authors, the methodology was
limited because the control group was not randomized
but rather consisted of the patients who decided not to
accept PADN. Surprisingly, also for the small size of the 2
groups, the baseline characteristics ended up to be perfectly
comparable. It is not clear why patients who undergone
PADN were withdrawn abruptly from the approved medical
therapy (but not oxygen therapy). In fact, PADN should
have been performed in addition to the current medical
treatment to match the medical treatment of the control
group.
Galiè and Manes JACC Vol. 62, No. 12, 2013
Pulmonary Arterial Hypertension Therapy September 17, 2013:1101–2
1102Last, but not the least, the safety of PADN cannot be
established with this 3-month study: 1 patient died of sepsis,
and the possible detrimental effect of the ablation procedure
on the pulmonary vessel wall potentially leading to aneu-
rysmal dilation cannot be excluded (6). It is also not clear
whether the patients were able to withdraw oxygen therapy
after PADN or had to up-titrate it. In fact, PADN may
theoretically blunt the hypoxic vasoconstrictive reﬂex that is
important for the appropriate ventilation to perfusion
matching of the lungs.
The search for additional treatment resources for PAH
has resulted in ultimate failures even if the initial efﬁcacy and
safety experience in single centers was very encouraging.
Inhaled vasoactive intestinal peptide was shown to
markedly improve hemodynamics and exercise capacity in
idiopathic PAH patients in a single-center study (7), but this
was not conﬁrmed in a formal and relatively large multi-
center RCT (8). Very innovative treatments such as stem cell
therapy were also proposed in the past, and initial experience
in humans appeared quite promising (9). However, after 6
years, no additional information was available from the
authors of this apparently revolutionary paper, nor have
other groups been able to obtain similar results. Reproduc-
ibility of results is one of the basic points of the scientiﬁc
method, and this is even more important if clinical data are
provided from a single-center experience.
Failures have also been observed when an appropriate
development plan was followed. For example, the endothelin
receptor antagonist sitaxsentan was withdrawn from the
market after several cases of death due to severe liver toxicity
that was not properly identiﬁed in the phase II and III studies
(10). The tyrosine kinase inhibitor imatinib was recently
withdrawn from the regulatory approval process for insufﬁ-
cient data on the efﬁcacy-to-safety ratio collected in the phase
II and III studies, which included, collectively, about 300
patients (11). Proper safety evaluation requires a long-term
follow-up and an appropriate number of patients.
The challenging paper of Chen et al. (4) should be
considered as a very preliminary proof-of-principle study
that requires a formal and large multicenter RCT to
appropriately evaluate a possible new area for the treatment
of PAH patients. Strict diagnostic inclusion and exclusion
criteria need to be applied. The authors report that the
speciﬁc PADN catheter is going to be patented, and we
imagine that programs for commercialization are also
ongoing. Surprisingly, new catheters can be sold and utilized
based only on general technical safety requirements, even if
they have not been tested in formal clinical trials as required
for experimental drugs. The expertise for ablatingarrhythmias and for renal denervation in resistant hyper-
tension is quite prevalent in clinical practice, and the risk for
the application of PADN in clinical practice before clear
evidence of efﬁcacy and safety is available is unfortunately
high. This would not be the good clinical practice that is
required by our patients. We should be sure that we can
provide them with established hope, and avoid any potential
hype.Reprint requests and correspondence: Prof. Nazzareno Galiè or
Dr. Alessandra Manes, Bologna University Hospital, Pavillion 21,
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